FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4282968462> ?p ?o ?g. }

• W4282968462 endingPage "1038" @default.
• W4282968462 startingPage "1038" @default.
• W4282968462 abstract "Abstract Introduction: In pancreatic ductal adenocarcinoma (PDAC), low patient survival rate remains a problem. The activating point mutation of KRAS on codon-12 is present in 70-95% of PDAC cases and so far, no success has been achieved to inhibit KRAS. KRASG12D regulates cell proliferation, differentiation, apoptosis; recent preliminary and published studies show high Galectin-1 (Gal-1) levels in both PDAC and stromal cells, which modulate tumor microenvironment and metastasis. Therefore, we have developed a novel combination therapy for PDAC by targeting mutated KRASG12D and Gal-1 to target both proliferation and metastasis in PDAC. This includes the delivery of KRASG12D inhibiting siRNA (siKRASG12D) using a superparamagnetic iron oxide nanoparticle (SPION) and a galectin inhibitor. Methods: Our patented SPION nano-formulation was used to deliver siKRASG12D and investigated in conjunction with Gal-1 inhibitor for its anticancer efficacy. Particles were investigated for size, physico-chemical characterization (Dynamic light scattering), hemocompatibility (hemolysis assay) and the complexation of siKRAS (gel retardation assay). Cellular internalization and uptake of the particles were investigated. Anti-cancer efficacy was determined using in vitro functional assays for cell viability (MTT), migration (Boyden chambers), invasion (Matrigel), clonogenicity, tumor spheroid formation, and in a mouse model. Results: Our results demonstrate optimal particle size/zeta potential of SP-siKRAS formulation. SP-siKRAS efficiently internalized in PDAC cells and suppressed KRASG12D as well as its downstream targets, YAP and PDL-1. Combined targeting of siKRAS and Gal-1 inhibited cell proliferation. It inhibited cell proliferation, clonogenicity, migration, and invasion of PDAC cells. This resulted in activation of death related mechanisms, such as Bax, bcl-2, PARP cleavage in KRASG12D cells. Interestingly, the formulation was highly effective in inhibiting KRASG12D and growth of tumor spheroid in 3D cell models, which recapitulate the heterogeneity and pathophysiology of PDAC. This further provides a clinical validation demonstrating potential of SP-siKRAS particles to efficiently silence KRAS expression. SP-siKRAS also exhibited hemocompatibility and stability suggesting its potential of silencing KRAS without being toxic to the body. The formulation efficiently exhibited KRasG12D silencing and inhibited tumor growth and metastasis in nude mice. Conclusion: This gene therapy targeting KRAS G12D mutation with a Gal-1 inhibition has a potential to modulate the oncogenic network and tumor microenvironment resulting in the repression of growth, metastasis, chemoresistance, and improvement in patient survival. This study will develop a novel sustainable therapeutic approach to target PDAC growth and improve patient survivability. Citation Format: Ana I. Martinez Bulnes, Poornima Shaji, Nirnoy Dan, Melida Cantu, Shabnam Malik, Stephen Behrman, Swathi Holla, Murali Mohan Yallapu, Meena Jaggi, Subhash C. Chauhan, Sheema Khan. Novel therapy targeting mutant-KRASG12D and galectin-1 in pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 1038." @default.
• W4282968462 created "2022-06-17" @default.
• W4282968462 creator A5013641421 @default.
• W4282968462 creator A5023184253 @default.
• W4282968462 creator A5029836145 @default.
• W4282968462 creator A5030239872 @default.
• W4282968462 creator A5034011054 @default.
• W4282968462 creator A5041474939 @default.
• W4282968462 creator A5051530309 @default.
• W4282968462 creator A5056093808 @default.
• W4282968462 creator A5061424018 @default.
• W4282968462 creator A5068753789 @default.
• W4282968462 creator A5088921600 @default.
• W4282968462 date "2022-06-15" @default.
• W4282968462 modified "2023-09-27" @default.
• W4282968462 title "Abstract 1038: Novel therapy targeting mutant-KRASG12D and galectin-1 in pancreatic cancer" @default.
• W4282968462 doi "https://doi.org/10.1158/1538-7445.am2022-1038" @default.
• W4282968462 hasPublicationYear "2022" @default.
• W4282968462 type Work @default.
• W4282968462 citedByCount "0" @default.
• W4282968462 crossrefType "journal-article" @default.
• W4282968462 hasAuthorship W4282968462A5013641421 @default.
• W4282968462 hasAuthorship W4282968462A5023184253 @default.
• W4282968462 hasAuthorship W4282968462A5029836145 @default.
• W4282968462 hasAuthorship W4282968462A5030239872 @default.
• W4282968462 hasAuthorship W4282968462A5034011054 @default.
• W4282968462 hasAuthorship W4282968462A5041474939 @default.
• W4282968462 hasAuthorship W4282968462A5051530309 @default.
• W4282968462 hasAuthorship W4282968462A5056093808 @default.
• W4282968462 hasAuthorship W4282968462A5061424018 @default.
• W4282968462 hasAuthorship W4282968462A5068753789 @default.
• W4282968462 hasAuthorship W4282968462A5088921600 @default.
• W4282968462 hasConcept C121608353 @default.
• W4282968462 hasConcept C1491633281 @default.
• W4282968462 hasConcept C185592680 @default.
• W4282968462 hasConcept C2778608917 @default.
• W4282968462 hasConcept C2779013556 @default.
• W4282968462 hasConcept C2780210213 @default.
• W4282968462 hasConcept C2780394083 @default.
• W4282968462 hasConcept C2781187634 @default.
• W4282968462 hasConcept C502942594 @default.
• W4282968462 hasConcept C526805850 @default.
• W4282968462 hasConcept C53227056 @default.
• W4282968462 hasConcept C54355233 @default.
• W4282968462 hasConcept C55493867 @default.
• W4282968462 hasConcept C62112901 @default.
• W4282968462 hasConcept C86803240 @default.
• W4282968462 hasConcept C96232424 @default.
• W4282968462 hasConceptScore W4282968462C121608353 @default.
• W4282968462 hasConceptScore W4282968462C1491633281 @default.
• W4282968462 hasConceptScore W4282968462C185592680 @default.
• W4282968462 hasConceptScore W4282968462C2778608917 @default.
• W4282968462 hasConceptScore W4282968462C2779013556 @default.
• W4282968462 hasConceptScore W4282968462C2780210213 @default.
• W4282968462 hasConceptScore W4282968462C2780394083 @default.
• W4282968462 hasConceptScore W4282968462C2781187634 @default.
• W4282968462 hasConceptScore W4282968462C502942594 @default.
• W4282968462 hasConceptScore W4282968462C526805850 @default.
• W4282968462 hasConceptScore W4282968462C53227056 @default.
• W4282968462 hasConceptScore W4282968462C54355233 @default.
• W4282968462 hasConceptScore W4282968462C55493867 @default.
• W4282968462 hasConceptScore W4282968462C62112901 @default.
• W4282968462 hasConceptScore W4282968462C86803240 @default.
• W4282968462 hasConceptScore W4282968462C96232424 @default.
• W4282968462 hasIssue "12_Supplement" @default.
• W4282968462 hasLocation W42829684621 @default.
• W4282968462 hasOpenAccess W4282968462 @default.
• W4282968462 hasPrimaryLocation W42829684621 @default.
• W4282968462 hasRelatedWork W2056270197 @default.
• W4282968462 hasRelatedWork W2154708791 @default.
• W4282968462 hasRelatedWork W2556446038 @default.
• W4282968462 hasRelatedWork W2582912872 @default.
• W4282968462 hasRelatedWork W2600717990 @default.
• W4282968462 hasRelatedWork W2968996136 @default.
• W4282968462 hasRelatedWork W3008112408 @default.
• W4282968462 hasRelatedWork W3013358603 @default.
• W4282968462 hasRelatedWork W4283771460 @default.
• W4282968462 hasRelatedWork W4304116770 @default.
• W4282968462 hasVolume "82" @default.
• W4282968462 isParatext "false" @default.
• W4282968462 isRetracted "false" @default.
• W4282968462 workType "article" @default.